newsfilter
← Latest News
GlobeNewswire·

Kaleido Biosciences and the COPD Foundation Announce a Strategic Collaboration to Advance KB109 into Phase 2 Clinical Trial

LEXINGTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (NASDAQ:KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, tod